US8853298B2 - Fiber wadding for filling bone defects - Google Patents
Fiber wadding for filling bone defects Download PDFInfo
- Publication number
- US8853298B2 US8853298B2 US13/350,569 US201213350569A US8853298B2 US 8853298 B2 US8853298 B2 US 8853298B2 US 201213350569 A US201213350569 A US 201213350569A US 8853298 B2 US8853298 B2 US 8853298B2
- Authority
- US
- United States
- Prior art keywords
- fiber wadding
- fiber
- measured
- wadding
- accordance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/755—Polymers containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/32—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/04—Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2002/4495—Joints for the spine, e.g. vertebrae, spinal discs having a fabric structure, e.g. made from wires or fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T442/00—Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
- Y10T442/20—Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
- Y10T442/2033—Coating or impregnation formed in situ [e.g., by interfacial condensation, coagulation, precipitation, etc.]
Definitions
- the present invention relates to bioactive materials which are useful as bone-repairing materials for filling bone defects and may be used in the fields, such as oral or maxillofacial surgery and orthopedic surgery. More specifically, the present invention relates to a fiber wadding for filling bone defects.
- the fiber wadding has a three-dimensional structure and comprises a bioresorbable-biodegradable resin.
- bioactive materials when buried or implanted in bone defects, react with the bone and are directly chemically combined with the bone. These materials are called bioactive materials and are further classified into superficial bioactive materials, where the reaction occurs only on the surface of the materials; and bioresorbable materials, where the reaction occurs even inside the materials and the materials are gradually replaced with the bone.
- exemplary commercialized superficial bioactive materials include hydroxyapatite ceramics (e.g., trade name APACERAMTM supplied by HOYA CORPORATION, Japan); and exemplary commercialized bioresorbable materials include beta phase tricalcium phosphate ceramics (e.g., trade name OSferionTM supplied by Olympus Terumo Biomaterials Corp., Japan).
- Calcium carbonate (CaCO 3 ) and gypsum (CaSO 4 H 2 O) are also known to be bioresorbable. These substances, however, have low strength and toughness and are difficult to be machined.
- biodegradable polymers such as poly(lactic acid)s, poly(glycolic acid)s, copolymers of them, and polycaprolactones are highly flexible and are easy to be machined.
- the biodegradable polymers do not show osteogenic ability (bone forming ability) because their biodegradability is derived from the phenomenon that they are degraded in vivo and are discharged therefrom.
- JP-A Japanese Unexamined Patent Application Publication No. 2001-294673 discloses a process for the preparation of a bioresorbable material by combining a poly (lactic acid) and a calcium carbonate.
- this document refers to a process for synthesizing a bioresorbable material by mixing a calcium carbonate containing vaterite as a principal component with a biodegradable polymer compound such as a poly (lactic acid), which vaterite is highly soluble in water among such calcium carbonates.
- a biodegradable polymer compound such as a poly (lactic acid)
- This technique is also advantageous in that the pH is always maintained around neutrality, because even when the poly (lactic acid) is decomposed to be acidic, the acidity is neutralized by the buffering effects of the calcium carbonate as dissolved.
- the affected area (bone defect) is incised and a dense or porous material, having such a size as to fill the affected area sufficiently, is directly implanted therein, or a granular material is charged into the affected area.
- JP-A Japanese Unexamined Patent Application Publication
- guided bone regeneration membrane has a bi-layer structure including a first nonwoven fabric layer and a second nonwoven fabric layer, in which the first nonwoven fabric layer contains a silicon-releasable calcium carbonate and a biodegradable resin as principal components, and the second nonwoven fabric layer contains a biodegradable resin as a principal component.
- M3T3-E1 cells murine osteoblast-like cells
- osteogenesis osteogenesis
- This membrane is not usable as a material for filling bone defects because it has a small thickness of from 230 to 300 ⁇ m.
- the bulk density of such membranes estimated to be about 0.4 g/cm 3 or more, is generally too high to be used as a material for filling bone defects.
- an object of the present invention is to provide a fiber wadding formed of a bioresorbable material for filling bone defects, which material may have a sustained release system with such a chemical composition as to guide bone reconstruction ability effectively and has a three-dimensional structure having such a flexibility as to fit in an affected area satisfactorily.
- the present invention relates to a fiber wadding for filling bone defects, wherein the fiber wadding having a flocculent three-dimensional structure including a plurality of fibers.
- the fibers contain a biodegradable resin as a principal component and contain or bear a siloxane.
- fibers in a fiber wadding of the invention may be coated with hydroxyapatite on their surfaces.
- the biodegradable resin may be poly(lactic acid) or a copolymer thereof.
- the fibers may contain siloxane dispersed in calcium carbonate micro-particles.
- the present invention relates a fiber wadding for filling bone defects comprising a plurality of fibers comprising a biodegradable resin and vaterite phase calcium carbonate micro-particles, wherein the plurality of fibers are entangled with each other in three dimensional directions to form a fiber wadding such that a bulk density of the fiber wadding is 0.005-0.3 g/cm 3 .
- FIG. 1 shows an explanatory view of a common electrospinning technique
- FIG. 2 shows an explanatory view of an electrospinning technique according to an embodiment of the present invention
- FIG. 3 depicts the appearance of a three-dimensional structure of a fiber wadding prepared in Example 1, indicated with 10-mm squares;
- FIG. 4 shows a scanning electron micrograph (SEM) of fibers constituting the three-dimensional structure of a fiber wadding prepared in Example 1;
- FIG. 5 is a graph showing the amounts of silicon ions released from a three-dimensional structure of Si-PLA 15 , prepared in Example 1, into a cell culture medium;
- FIG. 6 is a graph showing the amounts of silicon ions released from a three-dimensional structure of Si-PLA 50 , prepared in Example 1, into a cell culture medium;
- FIG. 7 shows a scanning electron micrograph (SEM) of fibers constituting a Si—CaCO 3 /PLA three-dimensional structure prepared in Example 2;
- FIG. 8 shows a scanning electron micrograph (SEM) of fibers constituting a Si—CaCO 3 /PLA three-dimensional structure obtained after soaking in 1.5 SBF, the Si—CaCO 3 /PLA three-dimensional structure prepared in Example 2;
- FIG. 9 depicts an X-ray diffraction patterns of the Si—CaCO 3 /PLA three-dimensional structure prepared in Example 2, before and after soaking in 1.5 SBF;
- FIG. 10 is a graph showing the results in cell proliferation testing of a Si—CaCO 3 /PLA three-dimensional structure coated with hydroxyapatite prepared in Example 2 and of a comparative sample.
- FIG. 11 shows a SEM photo of micro-particles of a silicon releasable calcium carbonate obtained by carbonation process.
- FIG. 12 shows an explanatory view of an electrospinning technique according to an embodiment of the present invention
- FIG. 13 (A) shows an explanatory view of measurement of bulk density of the fiber wadding prepared in Example 3.
- FIG. 13 (B) shows an explanatory view of measurement of compressibility of the fiber wadding prepared in Example 3, in which a weight is placed on a cover.
- FIG. 13 (C) is an explanatory view of measurement of compression recovery of the fiber wadding prepared in Example 3, in which the weight is removed from the cover.
- Embodiments of the present invention relates to bioactive materials for filling bone defects.
- the materials comprise fiber wadding.
- Such a material has a flocculent three-dimensional structure of a fibrous substance that comprises a biodegradable resin as a principal component.
- the fibrous substance contains or bears a siloxane.
- a flocculent three-dimensional (3D) structure is a loose fluffy 3D structure.
- a biomaterial of the invention having such a loose fluffy 3D structure may be defined by various physical/chemical parameters, such as its weight, bulk density, compressibility, compression recovery ability, as described herein. These physical/chemical parameters may be determined using known standard methods, such as the Japanese Industrial Standard (JIS) methods, particularly JIS L 1097 method.
- JIS Japanese Industrial Standard
- a siloxane is any chemical compound composed of units of the form (R 2 SiO) n , where R is a hydrogen atom or a hydrocarbon group (e.g., methyl, ethyl, propyl, and butyl). Siloxane has a backbone comprising alternating Si and O.
- a siloxane suitable for use with embodiments of the invention can be any siloxane that can release Si in vivo. See e.g., Wakita et al., “ Preparation of electrospun siloxane - poly ( lactic acid )- vaterite hybrid fibrous membranes for guided bone regeneration ,” Compos. Sci. Technol., 2010; 70: 1889-1893.
- Bioactive materials of the invention may be prepared using electrospinning techniques. Electrospinning uses an electrical charge to draw very fine (typically on the micro or nano scale) fibers from a liquid or a slurry. When a sufficiently high voltage is applied to a liquid droplet, the body of the liquid becomes charged. The electrostatic repulsion in the droplet would counteract the surface tension and the droplet is stretched. When the repulsion force exceeds the surface tension, a stream of liquid erupts from the surface. This point of eruption is known as a Taylor cone. If molecular cohesion of the liquid is sufficiently high, the stream does not breakup and a charged liquid jet is formed.
- the mode of current flow changes from ohmic to convective as the charge migrates to the surface of the fiber.
- the jet is then elongated by a whipping process caused by electrostatic repulsion initiated at small bends in the fiber, until it is finally deposited on a grounded collector.
- the elongation and thinning of the fiber resulting from this bending instability leads to the formation of uniform fibers with nanometer-scale diameters.
- the voltage is normally applied to the solution or slurry in a regular electrospinning process
- the voltage is applied to the collector, not to the polymer solution (or slurry), and, therefore, the polymer solution is grounded.
- the polymer solution or slurry is sprayed into fibers while applying the voltage in this manner, and the fibers are entangled to form a three-dimensional structure.
- a material for filling bone defects having a three-dimensional structure and being satisfactorily flexible can also be obtained by carrying out the improved electrospinning technique, followed by soaking the electrospun material in a buffer solution that is supersaturated with hydroxyapatite.
- biodegradable resins usable with embodiments of the invention include synthetic polymers, such as polyethylene glycols (PEGs), polycaprolactones (PCLs), poly(lactic acids) (PLAs), polyglycolic acids (PGAs), and copolymers of PEG and PCL; and natural polymers, such as fibrin, collagen, alginic acid, hyaluronic acid, chitin, and chitosan.
- Preferred examples of the biodegradable resin include a poly(lactic acid) (PLA); and a copolymer of a poly(lactic acid) and a poly(glycolic acid) (PGA) (i.e., lactic acid-glycolic acid copolymer).
- a material for filling bone defects may be produced in the following manner. Initially, a solution is prepared by dissolving a biodegradable resin (such as PLA) in a suitable solvent, e.g., chloroform (CHCl 3 ) and/or dichloromethane. An aqueous solution of aminopropyltriethoxysilane (APTES) is added to the solution. In this procedure, the weight ratio of PLA:APTES (PLA to APTES) is possibly from 1:0.01 to 1:0.5, but is preferably from 1:0.01 to 1:0.05 (by weight).
- a biodegradable resin such as PLA
- a suitable solvent e.g., chloroform (CHCl 3 ) and/or dichloromethane.
- An aqueous solution of aminopropyltriethoxysilane (APTES) is added to the solution.
- the weight ratio of PLA:APTES is possibly from 1:0.01 to 1:0.5, but is preferably from 1:0.01 to 1
- the PLA has a molecular weight of from about 20 ⁇ 10 4 to about 30 ⁇ 10 4 kDa.
- concentration of the PLA in the solution is preferably from 4 to 12 percent by weight for satisfactory spinning.
- dimethylformamide and/or methanol may be added to the solution in a proportion of about 50 percent by weight or less relative to chloroform and/or dichloromethane.
- a liquid having a greater relative dielectric constant than that of the biodegradable resin may be added to the resulting solution to produce a spinning solution for the preparation of a three-dimensional structure.
- the biodegradable resin is a poly (lactic acid)
- a liquid having a greater relative dielectric constant than that of lactic acid may be added.
- liquids having a greater relative dielectric constant than that of lactic acid include methanol (relative dielectric constant: 32.6), ethanol (relative dielectric constant: 24.6), ethylene glycol (relative dielectric constant: 37.7), 1,2-propanediol (relative dielectric constant: 32.0), 2,3-butanediol, glycerol (relative dielectric constant: 42.5), acetonitrile (relative dielectric constant: 37.5), propionitrile (relative dielectric constant: 29.7), benzonitrile (relative dielectric constant: 25.2), sulfolane (relative dielectric constant: 43.3), and nitromethane (relative dielectric constant: 35.9).
- water relative dielectric constant: 70 to 80
- water is immiscible with and completely separated from chloroform and/or dichloromethane used as a solvent for the PLA.
- an amphiphilic liquid such as methanol, ethanol, propanol, and/or acetone
- amphiphilic liquids for use herein are not limited in their relative dielectric constants, as long as they are amphiphilic and satisfactorily miscible both with the solvent (such as chloroform and/or dichloromethane) and water.
- 0.5 to 5 g of the amphiphilic liquid (such as methanol, ethanol, propanol, and/or acetone) and 0.5 to 3 g of water may be added per 1 g of the PLA.
- a spinning solution may be further combined with a calcium carbonate to form a slurry (spinning slurry). This helps to speedup (acceleration) the step of soaking the electrospun article in a buffer solution that is supersaturated with hydroxyapatite to form an absorbable hydroxyapatite thereon.
- the absorbable hydroxyapatite helps to confer higher initial cellular adhesion.
- the amount of the calcium carbonate is possibly 60 percent by weight or less, because the calcium carbonate, if added in an amount of more than 60 percent by weight, maybe difficult to mix with the solution to give a homogeneous slurry. However, the calcium carbonate, if added in an amount less than 10 percent by weight, may not exhibit its advantageous effects remarkably.
- the solution or slurry may further include one or more inorganic substances which are usable in viva without problems.
- inorganic substances include hydroxyapatite, tricalcium phosphate, calcium sulfate, sodium phosphate, sodium hydrogen phosphate, calcium hydrogen phosphate, octacalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, and calcium chloride.
- a material for filling bone defects can also be a substance containing a biodegradable resin as a principal component and further containing or bearing a siloxane.
- This substance may be prepared by preparing calcium carbonate micro-particles bearing siloxane dispersed therein (Si—CaCO 3 ), typically by the method described in Japanese Unexamined Patent Application Publication (JP-A) No. 2008-100878; and mixing 60 percent by weight or less of the Si—CaCO 3 microparticles with PLA.
- the amount of the Si—CaCO 3 microparticles is preferably from 10 to 60 percent by weight relative to the PLA, as in the calcium carbonate.
- the substance is preferably prepared by kneading the PLA and Si—CaCO 3 micro-particles in predetermined proportions in a heating kneader to give a composite.
- the composite is then dissolved in the solvent to give a spinning solution.
- a charge is applied by a voltage supply 1 to a nozzle of a syringe 2 .
- a positive charge is applied to a spinning solution; and the solution is slowly extruded from the tip of the nozzle.
- the solution is stretched into fibers and travels toward a collector 3 which is connected with a ground electrode.
- the solvent of the solution evaporates, thereby forming a thin layer of nonwoven fabric of fibers.
- This technique does not produce a three-dimensional structure, even if one modifies the spinning conditions (such as the concentration of the spinning solution, the type of solvent contained in the solution, the supply speed of the solution, the spinning time, the applied voltage, and the distance between the nozzle and the collector). This is because the residual solution and the resin deposited on the collector 3 are charged by themselves and repel each other. The repulsion impedes the deposition in a thickness direction. In this connection, the fibrous resin derived from the solution deposits on the collector 3 would have most solvent evaporated. However, a trace amount of the solution deposits intact (i.e., containing the solvent) on the collector 3 .
- a three-dimensional structure of a fiber wadding can be formed by carrying out electrospinning while grounding the nozzle of the syringe 2 (i.e., without applying a charge thereto). At the same time, a positive charge is applied to the collector 3 .
- the spinning solution if a regular spinning solution is slowly extruded from the tip of the nozzle, the spinning solution would fall as droplets, because the solution is not charged.
- the spinning solution further contains a liquid, such as water, having a greater relative dielectric constant than that of the biodegradable resin, the liquid may be affected by the electric field, and the spinning solution may be drawn toward the collector by the action of polarization.
- the spinning solution is not charged by itself and readily forms three-dimensional deposits on the collector 3 , without suffering from electrostatic repulsion.
- the liquid (solution) may be divided into two or more strands and drawn from the nozzle of the syringe 2 toward the collector 3 . These strands are entangled to form a flocculent three-dimensional structure on the collector 3 .
- the spinning solution should have a somewhat low viscosity. If the spinning solution has an excessively high viscosity, it may not reach the collector 3 even when affected by the electric field. Accordingly, the diameter of the fibrous substance constituting the three-dimensional structure prepared according to embodiments of the invention may be substantially controlled by the viscosity of the spinning solution. When the spinning solution has a particularly low viscosity, the fibrous substance can deposit more easily to form a three-dimensional structure and the fibrous substance would more likely have smaller fiber diameters.
- the resulting fibrous substance has a fiber diameter in a range of about 0.05 ⁇ m to about 10 ⁇ m. It is acceptable not to apply a positive charge, but a negative charge, to the collector 3 , as long as the spinning solution can be drawn toward the collector by the action of polarization.
- the resulting three-dimensional structure of a fiber wadding may be cut into a piece of a required size, and the cut piece may be soaked in a buffer solution, containing calcium ions and phosphate ions and being saturated with respect to hydroxyapatite, to coat the surface of the fibrous skeleton with hydroxyapatite.
- a buffer solution containing calcium ions and phosphate ions and being saturated with respect to hydroxyapatite
- the buffer solution for use herein include a Tris buffer solution (pH 7.2 to 7.4) containing ions at a concentration substantially equal to the inorganic ion concentration in human plasma (simulated body fluid, or SBF) and a solution (1.5 SBF) containing ions in concentrations 1.5 times those of SBF.
- the 1.5 SBF is more advantageous, because the fibrous substance can be coated with hydroxyapatite more rapidly.
- a flexible material for filling bone defects which material has a three-dimensional structure of a fiber wadding including a fibrous substance, in which the fibrous substance contains a biodegradable resin, represented by poly(lactic acid) (PLA), as a principal component, and further contains or bears siloxane.
- a filling material for bone-repairing in which the surface of the fibrous substance constituting the three-dimensional structure is coated with hydroxyapatite.
- the coating with an absorbable hydroxyapatite can be easily performed by soaking the electrospun article in a buffer solution supersaturated with hydroxyapatite, and the coated absorbable hydroxyapatite helps to provide higher initial cellular adhesion.
- a fiber wadding for filling bone defects thus obtained has satisfactory flexibility derived from the three-dimensional structure constituted by the fibrous substance.
- Such fiber wadding shows high cell proliferation in cellular affinity assay using osteoblast-like cells (MC3T3-E1 cells) and excels in bone reconstruction ability.
- Bulk density of the fiber wadding of this embodiment is much lower than masking membrane of prior art as disclosed, for example, by JP-A 2009-61109.
- fibers of the fiber wadding are formed of a composite of silicon-releasable calcium carbonate and a biodegradable polymer.
- micro-particles of calcium carbonate of vaterite phase may be used as Si-releasable calcium carbonate, Si content of which may be, for example, 2 wt % (herein after referred to as 2SiV).
- Si releasable calcium carbonate can be obtained by using carbonation process, in which carbonate gas is sprayed into a suspension of a mixture of methanol, slaked lime, and organic silicon compound.
- FIG. 11 shows an SEM photo of the micro-particles of calcium carbonate, which is disclosed in the (JP-A) No. 2008-100878.
- diameters of the micro-particles vary and may be changed by adjusting the production conditions, preferable range of the diameter of the micro-particles are approximately 0.5-1.5 ⁇ m.
- a composite of silicone releasable calcium carbonate and biodegradable polymer may be formed by heating/kneading a mixture of Silicon vaterite powders and polylactic acid or a copolymer of polylactic acid and polyglycolic acid. Molecular weights of the polylactic acid or a copolymer of polylactic acid and polyglycolic acid are preferably from 150000 to 300000. In order to obtain a desirable elasticity of the fiber wadding, the 2SiV content of the composite is preferably 30-40 wt %. This composite may be dissolved using a solvent (such as CHCL 3 ) to obtain a spinning solution. The spinning solution thus obtained may be processed into a fiber wadding using electrospinning techniques.
- a solvent such as CHCL 3
- a positive voltage is applied to the spinning solution in a state that a container of the collector filled with ethanol is grounded.
- the spinning solution is then made into fibers and the electrospun fibers are attracted and travel to the container of the collector, while solvent of the spinning solution is evaporated in the electric field during that process.
- Those fibers attracted to the container of the collector are accumulated in the ethanol of the container to form a cotton like structure.
- Outside diameter of fiber wadding of this embodiment is preferably from about 0.05 ⁇ m to about 30 ⁇ m, preferably from about 0.1 ⁇ m to about 20 ⁇ m, and more preferably from about 10 ⁇ m to about 20 ⁇ m.
- Bulk density of fiber wadding as measured in accordance with JIS L 1097 is from about 0.005 g/cm 3 to about 0.3 g/cm 3 , preferably from about 0.01 g/cm 3 to about 0.1 g/cm 3 , more preferably from about 0.014 g/cm 3 to about 0.021 g/cm 3 .
- Compressibility of the fiber wadding of this embodiment is from about 10% to about 55%, preferably from about 20% to about 55%, more preferably from 29% to 55%.
- Compression recovery of the fiber wadding of this embodiment is from about 5% to about 76%, preferably from about 7% to about 76%, more preferably from about 44% to about 58%.
- fiber wadding of the present invention is formed of Si releasable calcium carbonate and a biodegradable polymer, it shows high cell proliferation, and has an excellent bone reconstruction ability. Compared with masking membrane, the bulk density of a fiber wadding of the present invention is very low. In addition, a fiber wadding of the invention is flexible and has excellent elasticity. Therefore, it can be easily filled in the bone defects during surgery and can be implanted in the bone defects without gap (clearance).
- Poly(lactic acid) (PLA): PURASORB PL Poly(L-lactide), having a molecular weight of from 20 ⁇ 10 4 to 30 ⁇ 10 4 , is from PURAC Biochem (a division of CSM; Netherlands).
- APTES ⁇ -Aminopropyltriethoxysilane
- Siloxane-doped calcium carbonate (Si—CaCO 3 ): Vaterite containing a siloxane in terms of a silicon ion content of 2.9 percent by weight and prepared by using slaked lime (Microstar T; with a purity of 96% or more; Yabashi Industries Co., Ltd., Japan), methanol (analytical grade reagent; with a purity of 99.8% or more; Kishida Chemical Co., Ltd., Japan), APTES, and carbon dioxide gas (high-purity liquefied carbon dioxide gas; with a purity of 99.9%; Taiyo Kagaku Kogyo K.K., Japan).
- Applied voltage A voltage was applied to the plate collector at 25 kV, while the nozzle being grounded,
- APTES (1 g) was added to ultrapure water (0.5 g) with stirring to give a solution.
- the solution was added dropwise to an 8% by weight PLA solution in CHCl 3 so as to give an APTES content of 0.015 g and 0.050 g, respectively, followed by stirring.
- APTES was condensed to give a siloxane.
- To the resulting mixtures were added 1.5 g of ethanol and 1 g of ultrapure water to give spinning solutions.
- FIG. 3 depicts the appearance of the resulting three-dimensional structure (Si-PLA 15 ).
- FIG. 4 shows a scanning electron micrograph (SEM) of this steric structure, demonstrating that the steric structure is a flocculent structure including fibers having diameters of from several tens of nanometers to eight micrometers.
- the structures under this condition had a weight of 40 mg. The structures did not lose their flexibility and elasticity even after they were soaked in a cell culture medium and recovered therefrom.
- FIG. 5 and FIG. 6 show the release amounts of silicon ions when the steric structures were soaked in the cell culture medium as measured through inductively coupled plasma emission spectrometry.
- the data demonstrate that both the samples (steric structures) released a large amount of silicon ions on Day 1, and thereafter released silicon ions in a significantly decreased amount, but continued to release silicon ions at least up to Day 7.
- Si-PLA 50 released about 6.5 ppm of silicon ions on Day 1 but released 1 ppm or less of silicon ions from Day 6 to Day 7, showing only a slight difference from that in Si-PLA 15 .
- a Si—CaCO 3 /PLA three-dimensional structure was prepared by kneading PLA and Si—CaCO 3 in a heating kneader at 200° C. for 15 minutes to give a Si—CaCO 3 /PLA composite containing 40 percent by weight of Si—CaCO 3 ; mixing 1.67 g of the Si—CaCO 3 /PLA composite with 8.33 g of CHCl 3 to give a solution; adding 1.5 g of ethanol and 1 g of ultrapure water to the solution to give a spinning solution; and subjecting the spinning solution to electrospinning under the above-mentioned conditions.
- FIG. 7 is a scanning electron micrograph (SEM) of the Si—CaCO 3 /PLA three-dimensional structure, demonstrating that this steric structure is a structure including fine fibers having diameters of about 0.1 to about 3 ⁇ m and spherical calcium carbonate particles having diameters of about 1 ⁇ m embedded between the fibers.
- the fibers have small diameters, and spaces (clearances) between fibers are sufficiently large of about several tens of micrometers or more so as to give sufficient spaces to allow cells to enter therein.
- the release amount of silicon ions from this steric structure was determined by the procedure of Example 1 to find that the steric structure released silicon ions in amounts of 5.3 ppm on Day 1, 0.8 ppm from Day 2 to Day 3; 0.4 ppm from Day 4 to Day 5; and 0.4 ppm from Day 6 to Day 7, indicating that the release in trace amount of silicon ion continued.
- the steric structure was cut to a sample piece 10 mm wide 10 mm long and 10 mm thick, soaked in 40 ml of 1.5 SBF, and held at 37° C. for one day.
- the sample piece was thereafter recovered from 1.5 SBF and observed under a scanning electron microscope (SEM), to find that a large number of aggregated particles as shown in FIG. 8 precipitated and that there remained spaces of about several tens of micrometers so as to allow cells to enter therein.
- FIG. 9 shows X-ray diffraction patterns of the sample piece before and after soaking in the 1.5 SBF, demonstrating that peaks derived from hydroxyapatite were observed in the sample piece after the soaking.
- FIG. 10 shows how cellular numbers (in terms of cellular numbers per 1 cm 2 ) vary after the inoculation of murine osteoblast-like cells (MC3T3-E1) on the hydroxyapatite-coated steric structure and on a comparative sample (Thermanox: plastic disc for cell culture).
- the comparative sample Thermanox had been treated on its surface for improving cell proliferation and for use in cell culture.
- the data in FIG. 10 demonstrate that the steric structure gives much higher cell growth capability than that of the surface-treated comparative sample and is expected as a material which excels in bone reconstruction ability.
- M3T3-E1 cells murine osteoblast-like cells (MC3T3-E1 cells; Riken Institute of Physical and Chemical Research, Japan).
- Cell inoculation number 1 ⁇ 10 4 cells/well.
- ⁇ -MEM containing 10% fetal bovine serum
- Sample piece The sample 3D steric structure was cut to a piece 10 mm long, 10 mm wide, and 10 mm thick (i.e., a 10-mm cube).
- Cell counting method The measurement was performed using the Cell Counting Kit-8 (cellular growth/cellular toxicity analytical reagent; Dojindo Laboratories, Japan) in accordance with the protocols attached to the reagent.
- the fibers accumulated in ethanol at the collector are recovered from the collector ( FIG. 12 ).
- Samples 1-4 were prepared from the fiber wadding recovered from the collectors and analyzed. Bulk density, compressibility and compression recovery were measured in accordance with HS L 1097.
- Diameters of fibers were measured using a laser microscope from eighteen points. It was found that while the diameter of each fiber thus measured significantly varied, the distribution range of diameter was about 10 ⁇ m ⁇ 21 ⁇ m.
- Each of the samples 1-4 (average weight: 0.055 g) was placed in a glass cylinder having inner diameter of 22 mm.
- a circular glass cover having approximately the same diameter was placed on the fiber wadding in the glass cylinder.
- Height of fiber wadding (h 0 ) in the glass cylinder having the cover placed thereon was measured.
- the bulk density of the fiber wadding was calculated based on the volume of the fiber wadding thus measured and its weight. (shown in FIG. 13 (A)).
- Compressibility of the fiber wadding of samples 1-4 thus measured was: Sample 1: 45.56%, Sample 2: 34.90%, Sample 3: 29.01%, Sample 4: 37.80% (Average 36.82%).
- Sample 1 58.47%
- Sample 2 44.02%
- Sample 3 56.14%
- Sample 4 57.20% (Average 53.96%).
- JIS Japanese Industrial Standards
- JIS Z 8703 standard condition of test room
- test samples Take pieces of wadding out of an unpackaged product and leave each piece in the room for more than 8 hours. Then, randomly pick samples for testing. The test samples of 20 ⁇ 20 cm size are piled up such that mass weight thereof becomes about 40 g. Pieces of test samples necessary for conducting the test are left in that state for about one hour.
- the tests could include testing for color, specific volume (bulk), compressibility (compression, recovery), fiber length, and quality.
- Specific volume is measured by measuring the weight of the test samples prepared as described above. A thick plate (a flat plate of 20 ⁇ 20 cm in size and 0.5 g/cm 2 ) is placed on a test piece and a weight A (2 Kg) is placed thereon for 30 minutes. Then, the weight A is removed and the test sample is left for 30 minutes in that state. This procedure is repeated three times. After the weight A is removed and left for thirty minutes in that state, the heights of the sample at four corners are measured and an average height is obtained. Specific volume is calculated using the following formula. The test should be performed with three samples and an average of the three samples is obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Compressibility (%)=(h 0 −h 1)/h 0×100
Compressibility recovery (%)=(h 2 −h 1)/(h 0 −h 1)×100
Specific volume (cm3/g)−(20×20×h 0)/10)/W
wherein h0 is an average value of the height at four corners of the test sample (mm), and W is the weight of the test sample (g). The specific volume (cm3/g) can be readily converted into bulk density (g/cm3), if desired.
Compressibility (%)=(h 0 −h 1)/h 0)×100
Compressibility recovery (%)=(h 2 −h 1)/(h 0 −h 1)×100
-
- h0: average height at four corners before placing weight B thereon (mm).
- h1: average height at four corners with weight B placed thereon (mm)
- h2: average height at four corners after weight B is removed (mm).
Claims (11)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/350,569 US8853298B2 (en) | 2009-07-10 | 2012-01-13 | Fiber wadding for filling bone defects |
| CN 201220480662 CN203235057U (en) | 2012-01-13 | 2012-09-19 | Fibrous filler for filling bone defect |
| ZA2013/00247A ZA201300247B (en) | 2012-01-13 | 2013-01-10 | Fiber wadding for filling bone defects |
| MX2013000371A MX341924B (en) | 2012-01-13 | 2013-01-10 | Fiber wadding for filling bone defects. |
| MYPI2013000095A MY164129A (en) | 2012-01-13 | 2013-01-11 | Fiber wadding for filling bone defects |
| SG2013002332A SG192363A1 (en) | 2012-01-13 | 2013-01-11 | Fiber wadding for filling bone defects |
| BR102013000771A BR102013000771B1 (en) | 2012-01-13 | 2013-01-11 | fiber filling to fill bone defects |
| US14/495,649 US9539365B2 (en) | 2009-07-10 | 2014-09-24 | Fiber wadding for filling bone defects |
| US14/728,544 US9498561B2 (en) | 2009-07-10 | 2015-06-02 | Fiber wadding for filling bone defects |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009-163320 | 2009-07-10 | ||
| JP2009163320A JP2011015865A (en) | 2009-07-10 | 2009-07-10 | Material for filling bone defect and production method thereof |
| US12/707,302 US20110009522A1 (en) | 2009-07-10 | 2010-02-17 | Material for filling bone defects and production method thereof |
| JP2011-021790 | 2011-02-03 | ||
| JP2011021790A JP2012161363A (en) | 2011-02-03 | 2011-02-03 | Floc with sustained-release property of silicon and calcium, and method of manufacturing the same |
| US13/350,569 US8853298B2 (en) | 2009-07-10 | 2012-01-13 | Fiber wadding for filling bone defects |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/707,302 Continuation-In-Part US20110009522A1 (en) | 2009-07-10 | 2010-02-17 | Material for filling bone defects and production method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/495,649 Continuation US9539365B2 (en) | 2009-07-10 | 2014-09-24 | Fiber wadding for filling bone defects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20120136090A1 US20120136090A1 (en) | 2012-05-31 |
| US8853298B2 true US8853298B2 (en) | 2014-10-07 |
Family
ID=46127049
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/350,569 Active 2030-08-27 US8853298B2 (en) | 2009-07-10 | 2012-01-13 | Fiber wadding for filling bone defects |
| US14/495,649 Active US9539365B2 (en) | 2009-07-10 | 2014-09-24 | Fiber wadding for filling bone defects |
| US14/728,544 Active US9498561B2 (en) | 2009-07-10 | 2015-06-02 | Fiber wadding for filling bone defects |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/495,649 Active US9539365B2 (en) | 2009-07-10 | 2014-09-24 | Fiber wadding for filling bone defects |
| US14/728,544 Active US9498561B2 (en) | 2009-07-10 | 2015-06-02 | Fiber wadding for filling bone defects |
Country Status (1)
| Country | Link |
|---|---|
| US (3) | US8853298B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140242186A1 (en) * | 2007-09-06 | 2014-08-28 | Orthorebirth Co. Ltd. | Guided bone regeneration membrane and manufacturing method thereof |
| US20150079147A1 (en) * | 2009-07-10 | 2015-03-19 | Orthorebirth Co., Ltd. | Fiber wadding for filling bone defects |
| EP3902572A1 (en) | 2018-12-25 | 2021-11-03 | Orthorebirth Co., Ltd. | A bone regeneration material having a cotton-wool like structure formed of a plurality of electrospun fibers |
| WO2021261408A1 (en) | 2020-06-21 | 2021-12-30 | Orthorebirth Co., Ltd. | Osteoinductive bone regeneration material and production method of the same |
| US11369473B2 (en) | 2019-04-08 | 2022-06-28 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| US11779683B2 (en) | 2019-04-08 | 2023-10-10 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| WO2023228905A1 (en) | 2022-05-23 | 2023-11-30 | 国立大学法人名古屋工業大学 | Method for continuously producing biodegradable fiber material containing inorganic filler particles using wet spinning, and cotton-like bone regeneration material produced with said method |
| US11969521B2 (en) * | 2016-04-28 | 2024-04-30 | National University Corporation Nagoya Institute Of Technology | Method for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5718459B2 (en) | 2010-06-17 | 2015-05-13 | ワシントン・ユニバーシティWashington University | Biomedical patch with aligned fibers |
| CA2885682C (en) | 2012-09-21 | 2020-03-10 | Washington University | Biomedical patches with spatially arranged fibers |
| MY195227A (en) * | 2013-07-09 | 2023-01-11 | National Univ Corporation Nagoya Institute Technology | Bone Defect Filling Material, and Production Method Therefor |
| US11793877B2 (en) * | 2015-10-06 | 2023-10-24 | Rensselaer Polytechnic Institute | Controlled drug release from electrospun fibers |
| JP7254017B2 (en) * | 2016-04-05 | 2023-04-07 | エスジー ベンチャーズ ピーティーワイ リミテッド | Nanofiber mat containing ceramic particles with releasable dopants |
| US10632228B2 (en) | 2016-05-12 | 2020-04-28 | Acera Surgical, Inc. | Tissue substitute materials and methods for tissue repair |
| CA3227438A1 (en) | 2021-07-29 | 2023-02-02 | Acera Surgical, Inc. | Combined macro and micro-porous hybrid-scale fiber matrix |
| AU2022318569A1 (en) | 2021-07-29 | 2024-01-25 | Acera Surgical, Inc. | Particle-form hybrid-scale fiber matrix |
| US12167853B2 (en) | 2021-09-07 | 2024-12-17 | Acera Surgical, Inc. | Non-woven graft materials for nerve repair and regeneration |
| CN116199914A (en) * | 2021-11-30 | 2023-06-02 | 山东丰金生物工程有限公司 | Organosilicon crosslinked sodium hyaluronate hydrogel and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374774B2 (en) * | 1999-08-31 | 2008-05-20 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers |
| US20120058090A1 (en) * | 2007-02-14 | 2012-03-08 | Drexel University | Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475077B1 (en) | 1990-09-10 | 1996-06-12 | Synthes AG, Chur | Bone regeneration membrane |
| JPH07265337A (en) | 1994-03-31 | 1995-10-17 | Jms Co Ltd | Bioabsorbable protective film and method for producing the same |
| GB9721585D0 (en) | 1997-10-10 | 1997-12-10 | Geistlich Soehne Ag | Chemical product |
| US5919234A (en) | 1996-08-19 | 1999-07-06 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
| AU752357B2 (en) | 1998-01-23 | 2002-09-19 | Marcopore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
| JP3456941B2 (en) | 2000-04-12 | 2003-10-14 | 矢橋工業株式会社 | Method for producing polylactic acid complex containing calcium carbonate |
| JP2002085547A (en) | 2000-09-11 | 2002-03-26 | Gc Corp | Dental absorptive tissue regenerating membrane |
| US6641773B2 (en) | 2001-01-10 | 2003-11-04 | The United States Of America As Represented By The Secretary Of The Army | Electro spinning of submicron diameter polymer filaments |
| US20040101959A1 (en) | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
| JP2006187303A (en) | 2003-06-11 | 2006-07-20 | Sunstar Suisse Sa | Biocompatible membrane |
| JP2004105754A (en) | 2003-12-19 | 2004-04-08 | Jms Co Ltd | Bioabsorbable protective film |
| US20080296808A1 (en) | 2004-06-29 | 2008-12-04 | Yong Lak Joo | Apparatus and Method for Producing Electrospun Fibers |
| US7326043B2 (en) | 2004-06-29 | 2008-02-05 | Cornell Research Foundation, Inc. | Apparatus and method for elevated temperature electrospinning |
| US20100303881A1 (en) | 2006-02-02 | 2010-12-02 | The John Hopkins University | Therapeutic Electrospun Fiber Compositions |
| JP5131724B2 (en) | 2006-10-19 | 2013-01-30 | 矢橋工業株式会社 | Silicon-eluting calcium carbonate and method for producing the same |
| GB0702847D0 (en) | 2007-02-14 | 2007-03-28 | Smith & Nephew | Scaffold with increased pore size |
| JP5179124B2 (en) | 2007-09-06 | 2013-04-10 | 矢橋工業株式会社 | Bone regeneration inducing membrane and method for producing the same |
| US9410267B2 (en) | 2009-05-13 | 2016-08-09 | President And Fellows Of Harvard College | Methods and devices for the fabrication of 3D polymeric fibers |
| US8853298B2 (en) * | 2009-07-10 | 2014-10-07 | Nagoya Institute Of Technology | Fiber wadding for filling bone defects |
-
2012
- 2012-01-13 US US13/350,569 patent/US8853298B2/en active Active
-
2014
- 2014-09-24 US US14/495,649 patent/US9539365B2/en active Active
-
2015
- 2015-06-02 US US14/728,544 patent/US9498561B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374774B2 (en) * | 1999-08-31 | 2008-05-20 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers |
| US20120058090A1 (en) * | 2007-02-14 | 2012-03-08 | Drexel University | Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery |
Non-Patent Citations (3)
| Title |
|---|
| Hotta et a.I, "Preparation of poly(lactic acid) microfiber mats containing calcium carbonate particles by an electrospinning method", 11th Symposium on Ceramics, Biology and Biomimetics, Dec. 7, 2007, pp. 15, Japan. * |
| Obata el al., "Preparation of poly(lactic acid)/silicon-doped calcium carbonate composite fibrous mats by electrospinning", ISAEM-2008, Nagoya, Nov. 18-21, 2008, 1 page, Japan. * |
| Obata et al., PLA/Vaterite Composite Microfiber Membranes for GBR, IUMRS-ICA 2008, Dec. 9-13, 2008, 1 page, Japan. * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140242186A1 (en) * | 2007-09-06 | 2014-08-28 | Orthorebirth Co. Ltd. | Guided bone regeneration membrane and manufacturing method thereof |
| US10092650B2 (en) * | 2007-09-06 | 2018-10-09 | National University Corporation, Nagoya Institute of Technology | Guided bone regeneration membrane and manufacturing method thereof |
| US20150079147A1 (en) * | 2009-07-10 | 2015-03-19 | Orthorebirth Co., Ltd. | Fiber wadding for filling bone defects |
| US9498561B2 (en) | 2009-07-10 | 2016-11-22 | Orthorebirth Co. Ltd. | Fiber wadding for filling bone defects |
| US9539365B2 (en) * | 2009-07-10 | 2017-01-10 | Orthorebirth Co. Ltd. | Fiber wadding for filling bone defects |
| US11969521B2 (en) * | 2016-04-28 | 2024-04-30 | National University Corporation Nagoya Institute Of Technology | Method for manufacturing bone-regeneration material comprising biodegradable fibers by using electrospinning method |
| EP3902572A1 (en) | 2018-12-25 | 2021-11-03 | Orthorebirth Co., Ltd. | A bone regeneration material having a cotton-wool like structure formed of a plurality of electrospun fibers |
| US11369473B2 (en) | 2019-04-08 | 2022-06-28 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| US11779683B2 (en) | 2019-04-08 | 2023-10-10 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| US12485011B2 (en) | 2019-04-08 | 2025-12-02 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| WO2021261408A1 (en) | 2020-06-21 | 2021-12-30 | Orthorebirth Co., Ltd. | Osteoinductive bone regeneration material and production method of the same |
| WO2023228905A1 (en) | 2022-05-23 | 2023-11-30 | 国立大学法人名古屋工業大学 | Method for continuously producing biodegradable fiber material containing inorganic filler particles using wet spinning, and cotton-like bone regeneration material produced with said method |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150265750A1 (en) | 2015-09-24 |
| US9539365B2 (en) | 2017-01-10 |
| US9498561B2 (en) | 2016-11-22 |
| US20120136090A1 (en) | 2012-05-31 |
| US20150079147A1 (en) | 2015-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8853298B2 (en) | Fiber wadding for filling bone defects | |
| MX2013003089A (en) | Pressure control apparatus. | |
| Wang et al. | “Tree to bone”: lignin/polycaprolactone nanofibers for hydroxyapatite biomineralization | |
| US10814000B2 (en) | Guided bone regeneration membrane and manufacturing method thereof | |
| Poologasundarampillai et al. | Cotton-wool-like bioactive glasses for bone regeneration | |
| Cui et al. | Hydroxyapatite nucleation and growth mechanism on electrospun fibers functionalized with different chemical groups and their combinations | |
| Kasuga et al. | Siloxane-poly (lactic acid)-vaterite composites with 3D cotton-like structure | |
| Mozafari et al. | Biomimetic formation of apatite on the surface of porous gelatin/bioactive glass nanocomposite scaffolds | |
| US20060154063A1 (en) | Nanofiber construct and method of preparing thereof | |
| Tanner | Bioactive composites for bone tissue engineering | |
| Leonor et al. | Growth of a bonelike apatite on chitosan microparticles after a calcium silicate treatment | |
| Xie et al. | Alginate-controlled formation of nanoscale calcium carbonate and hydroxyapatite mineral phase within hydrogel networks | |
| US20110060413A1 (en) | Guided bone regeneration membrane and manufacturing method thereof | |
| SG192363A1 (en) | Fiber wadding for filling bone defects | |
| US20110009522A1 (en) | Material for filling bone defects and production method thereof | |
| Bil et al. | Bioactivity of polyurethane-based scaffolds coated with Bioglass® | |
| Cámara-Torres et al. | Boosting bone regeneration using augmented melt-extruded additive-manufactured scaffolds | |
| KR20210070523A (en) | Scaffolds for bone regeneration and method for producing the same | |
| US20110245922A1 (en) | Material for filling bone defects and production method thereof | |
| Paul et al. | Nanohydroxyapatite‐based composite materials and processing | |
| Mutlu et al. | Influence of boron incorporated biphasic calcium phosphate on mechanical, thermal, and biological properties of poly (vinylidene fluoride) membrane scaffold | |
| Rivero et al. | Nanocomposite electrospun micro/nanofibers for biomedical applications | |
| Watabe et al. | Surface modification of cotton-wool-like bone void fillers consisting of biodegradable polymer-based composite fibers containing calcium-salt particles | |
| Fraczek-Szczypta et al. | Polymer nanocomposite scaffolds modified with carbon nanotubes for tissue regeneration | |
| Isaji et al. | Preparation and Evaluation of a Poly (Lactic-co-glycolic Acid) Membrane Containing β-TCP |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: NAGOYA INSTITUTE OF TECHNOLOGY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KASUGA, TOSHIHIRO;OBATA, AKIKO;FUJIKURA, KIE;REEL/FRAME:027909/0944 Effective date: 20120223 Owner name: ORTHOREBIRTH CO. LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OTA, YOSHIO;YAO, XIANFENG;REEL/FRAME:027909/0969 Effective date: 20120222 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551) Year of fee payment: 4 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |